Cancer immunotherapy has a promising future despite suffering a major setback last Friday. Incyte Corporation (NASDAQ:INCY) announced that its trial drug epacadostat had failed to help melanoma patients, and the company is calling off the trial altogether.
Epacadostatwas meant to work together with Keytruda, Merck & Co., Inc. (NYSE:MRK)’s blockbuster cancer immunotherapy drug, which has earned the pharmaceutical company billions in revenue to help in boosting the immune system to fight cancer. The immune systems contains the T cells, which are able to different normal cells and leave alone and the foreign cells which they should attack and destroy. The main problem is that T cells resemble many cancer cells. Keytruda helps the T cells to correctly identify and destroy cancer cells. Drugs like Keytruda are referred to as “checkpoint inhibitors.”
Epacadostat was supposed to boost immunotherapy. The body produces an enzyme called IDO, which stops the T cells from doing the job they are supposed to do. Epacadostat stops the IDO enzyme from suppressing the T cells. It is an IDO inhibitor.
Incyte jhad hopped that epacadostat, working together with Keytruda, would help in fighting and defeating cancer more effectively and powerfully than Keytruda working alone. However, epacadostat failed in stopping the spread of cancer, and has also failed in helping in the overall survival. Following the failure, Incyte stock lost more 19% on Friday. Merck shares drop by almost 3%.
In a press release, Incyte chief medical officer Dr. Steven Stein said they are very disappointed that the trial failed to confirm the efficacy of epacadostat working with KEYTRUDA in patients with metastatic or unresectable melanoma. He added that despite the failure, they remain committed to transforming cancer treatment and will explore more ways on how IDO1 inhibition plus other novel mechanisms which can improve the outcomes for patients who are in need.
After calling off the trial, the company says it will be testing epacadostat for treatment of other cancer. According to Dr. Jason Luke, an oncologist at the University of Chicago, the study failed because the company concentrated on a very broad sample of patients.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.